About Texas Immuno-Oncology Biorepository (TIOB)

The Texas Immuno-Oncology Biorepository is a research facility that collects, catalogs and stores samples of biological material, such as urine, blood, stool, tissue, cells, DNA, RNA and protein, in an effort to improve our understanding of cancer

Our goal with the TIOB is to help researchers:

  • Analyze how different cells and immune systems respond to cancer treatment
  • Address why a cancer is resistant to treatment in some patients or why it returns in others
  • Study how to improve patient outcomes and survival rates
Video thumbnail

Our goal with the TIOB is to help researchers:

  • Identify how to find cancer earlier, when it may be easier to treat
  • Understand how healthy cells become ancer cells
  • Discover novel biomarkers to detect cancer sooner or predict how it may respond to treatment
  • Analyze how different cells and immune systems respond to cancer treatment
  • Address why a cancer is resistant to treatment in some patients or why it returns in others
  • Study how to improve patient outcomes and survival rates

Principal Investigator: Ronan Kelly, MD, MBA, FASCO

National Clinical Trials # NCT05371756

Member: International Society for Biological and Environmental Repositories (ISBER)

Laboratory Accreditation: College of American Pathologists (CAP) Biorepository Accreditation Program

 

TIOB facts

How is this different from other cancer research?

The TIOB was created to fuel research efforts, not to compete with them.

Research has led to the creation of many immunotherapies, like CAR-T, to help treat different cancers. We want to improve the understanding of how immunotherapies are performing in a real-world setting.

Through Baylor Scott & White Research Institute (BSWRI), we can safely collect biospecimens from a very large, and uniquely diverse, patient population in a biorepository, which is like a library for these samples. Those samples can then be studied for the purpose of identifying cancer earlier, improving patient outcomes, and analyzing changes that happen before or after treatment. Samples from a biorepository may help with many research studies over time without asking patients for new samples for each new study.

The data and biological samples we gather will allow researchers to dig into the microscopic nuances that can change how one patient responds to a treatment compared with another, or what small changes can be made to improve the effectiveness of a treatment option.

Who can participate?

  • Patients with confirmed or suspected cancer
  • Patients who expect to receive immunotherapy
  • Patients willing to donate blood and other biospecimen samples
  • Cancer types: skin, lung, breast, liver, kidney and bladder

How it works

Frequently asked questions

TIOB leadership

Ronan Kelly, MD, MBA, FASCO

Principal Investigator
Pukar Ratti

Pukar Ratti, MSChE, MSHCM, CIM, CCRP, FACMPE

System Director, Clinical Research and Operations
Dedra Preece

Dedra Preece, MHA, CCRP

Director, Clinical Research (Central Texas)
George Snipes

George Snipes, MD

Medical Director, System Biorepository and CAP Accreditation
Jennifer Finholt

Jennifer Finholt, MS

Director, System Biorepository
Shraddha Vyas

Shraddha Vyas, PhD

Research Investigator, Data Management and Analytics
Belen Gutierrez

Belen Gutierrez, MBA, CCRC

Program Manager

Contact Us

Texas Immuno-Oncology Biorepository (TIOB)
Baylor Scott & White Charles A. Sammons Cancer Center
3410 Worth Street, Suite 165,
Dallas, TX 75246


Phone: 214.818.2971
Fax: 214.820.3489
Email: TIOB@BSWHealth.org